Repligen

RGENNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$8.841 B

$180.71 +2.16%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

$48.9M

#1579 by earnings

Shares outstanding

56,435,621

Latest filing cover page

P/E ratio

180.8

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#15QiagenQGEN$9.23B
#16ImmunityBioIBRX$8.96B
#17RepligenRGEN$8.84B
#18VaxcytePCVX$8.77B
#19ImmunovantIMVT$7.68B

What if Repligen were worth as much as…

Open the what-if tool →

Gold $30.3T

$618,806.04

Per share 3,424× higher

Bitcoin $1.72T

$35,153.04

Per share 195× higher

Nvidia $5.48T

$112,009.09

Per share 620× higher

Or at a round number

$20.0B $50.0B $100.0B $200.0B

Where these numbers come from

Share counts and financials for Repligen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.